Amphastar Pharmaceuticals, Inc. Announces Launch of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
29
Amphastar Pharmaceuticals, Inc. Announces Launch of Primatene® MIST to Nationwide Retail Pharmacies

RANCHO CUCAMONGA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that Primatene ® MIST has been launched. Primatene ® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA-approved metered dose inhaler (MDI) for asthma in the over-the-counter (OTC) market in the United States. Primatene ® MIST is now available nationwide at Walgreens stores and online at Walgreens and CVS. It will also be available nationwide at CVS stores by mid-January. The Company is currently building additional inventory to provide Primatene ® MIST to more pharmacy chains and big box retail stores in the coming months.

Pipeline Information

The Company currently has four abbreviated new drug applications (“ANDAs”) filed with the FDA, which are targeting products with a market size of approximately $0.7 billion, three biosimilar products in development targeting products with a market size of approximately $14.0 billion, and 11 generic products in development targeting products with a market size of approximately $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2018. The Company’s proprietary pipeline includes an NDA for intranasal naloxone. The Company is currently developing four other proprietary products, which include injectable, inhalation and intranasal dosage forms.

Company Information

Amphastar is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation and intra-nasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company’s website at  www.amphastar.com .

Amphastar’s logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene ® , Amphadase ®  and Cortrosyn ® , are the property of Amphastar Pharmaceuticals, Inc.

Forward Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, including DMFs, the timing of product launches and the timing of products becoming available on the market,  acquisitions and other matters related to its current products, pipeline of product candidates and other future events. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates, and projections regarding Amphastar’s business, operations, and other similar or related factors. Words such as “may,” “might,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission. You can locate these reports through the Company’s website at http://ir.amphastar.com and on the SEC’s website at www.sec.gov .  Amphastar undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause Amphastar’s expectations to change.

Investor Contact: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 980-9484

Noted products are trademarks or registered trademarks of their respective owners. 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 70

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 72

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Finance Secures Legal Win with Permanent Injunction

Updated Category News Views 1608

Legal Victory for Beyond Finance Against Former Executive In a significant legal development, Beyond Finance has successfully secured a permanent injunction against its former Chief Marketing Officer, Grant Eckert. This ruling was handed down by a Texas court, illustrating a firm stance by Beyond Finance in upholding its non-competition agreements. Details of the Case The...

Continue Reading
Analyzing the Decline in Serve Robotics Inc's Short Interest

Updated Category News Views 174

Understanding Serve Robotics Inc's Short Interest Trends Serve Robotics Inc (NYSE: SERV) has recently reported a noticeable decline in its short interest, down by 6.79% from the previous report. As of the latest data, around 13.64 million shares have been sold short, representing 19.08% of all available shares for trading. Notably, it would take traders an average of 1.53...

Continue Reading
FAT Brands Stock Trend Analysis: 52-Week Low Challenges

Updated Category News Views 147

FAT Brands Faces Market Challenges at 52-Week Low In recent trading activities, FAT Brands Inc., trading under the ticker FATBB, has encountered significant market challenges, recently dropping to a 52-week low of $4.13. This recent low is indicative of the difficulties the company is facing amidst a shifting economic environment. Market Dynamics Affecting FAT Brands...

Continue Reading
Kraig Labs Leads the Charge in Revolutionary Silk Fabrication

Updated Category News Views 221

Kraig Labs: Pioneering Spider Silk Innovation In recent years, the realm of biotechnology has witnessed significant advancements, particularly in the production of specialized materials. Kraig Biocraft Laboratories, or Kraig Labs, stands at the forefront of this innovative field, redefining the future of spider silk. This biotechnology company has gained recognition for...

Continue Reading
The Safar Twins Unveil Stunning Short Film Resonance

Updated Category News Views 395

The Safar Twins Unveil a Captivating New Short Film Written and directed by interdisciplinary artist Parsa Afsharjavan, Resonance is an upcoming cinematic gem that promises to captivate audiences worldwide. This 30-minute short film, inspired by the intricate themes of duality and identity, is set to premiere in 2025 and navigate the global festival circuit. Introducing...

Continue Reading